Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying leading-edge structural biology and unique computational chemistry tools to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology.


Others are building towards a future transformation of the drug development process…for Ventus, that future is already here.

Our proprietary drug discovery platform, ReSOLVE™, gives us unique insights into protein motion and the ability to create blueprints of optimal drug molecules, in a process that disrupts virtual screening and allows Ventus to transition from in silico to the lab quickly and efficiently.

We screened our first target in 2020 and nominated three development candidates in 2022: VENT-03, a potential first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a systemic NLRP3 inhibitor. We entered the clinic with our most advanced program, VENT-02, in 2023 and the Phase 1 clinical trial is ongoing.

These programs exemplify our unique capabilities and ability to generate first-and best-in-class drugs for immunology targets with franchise potential, by addressing prevalent diseases with relevant unmet needs.